Bryn Mawr Capital Management LLC Increases Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Bryn Mawr Capital Management LLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 365.6% in the 4th quarter, Holdings Channel.com reports. The firm owned 59,260 shares of the medical research company’s stock after purchasing an additional 46,531 shares during the quarter. Bryn Mawr Capital Management LLC’s holdings in Amgen were worth $15,446,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the business. AMF Tjanstepension AB increased its stake in shares of Amgen by 16.9% in the 3rd quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company’s stock worth $38,825,000 after purchasing an additional 17,387 shares in the last quarter. Swedbank AB increased its position in Amgen by 1.1% in the third quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock worth $173,639,000 after buying an additional 5,751 shares in the last quarter. Copeland Capital Management LLC purchased a new stake in Amgen in the third quarter worth about $132,000. Foundations Investment Advisors LLC raised its stake in shares of Amgen by 11.5% in the third quarter. Foundations Investment Advisors LLC now owns 16,656 shares of the medical research company’s stock worth $5,367,000 after buying an additional 1,716 shares during the period. Finally, Calton & Associates Inc. lifted its position in shares of Amgen by 18.7% during the 3rd quarter. Calton & Associates Inc. now owns 844 shares of the medical research company’s stock valued at $272,000 after buying an additional 133 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on AMGN shares. Bank of America lifted their price target on shares of Amgen from $256.00 to $275.00 and gave the company an “underperform” rating in a report on Thursday, February 6th. StockNews.com cut shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Leerink Partners cut their price target on Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Citigroup lowered their price objective on Amgen from $310.00 to $295.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Finally, Redburn Partners dropped their price objective on Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $314.09.

Amgen Trading Up 0.5 %

Shares of NASDAQ AMGN opened at $294.27 on Thursday. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The business’s 50 day moving average is $275.15 and its two-hundred day moving average is $300.77. The stock has a market capitalization of $158.18 billion, a P/E ratio of 38.98, a PEG ratio of 2.53 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, research analysts expect that Amgen Inc. will post 20.6 EPS for the current year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a yield of 3.24%. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio is presently 126.09%.

Insider Buying and Selling

In other Amgen news, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the sale, the executive vice president now owns 28,987 shares in the company, valued at $8,496,669.44. This trade represents a 46.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the business’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the sale, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 35,405 shares of company stock valued at $10,410,596 in the last ninety days. 0.69% of the stock is owned by company insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.